0%) 3 (13.0%) 0.50 Peritoneum, n (%) 5 (16.7%) 4 (17.4%) 0.95 Lymph nodes, n (%) 2 (6.7%) 3 (13.0%) 0.43 Lungs,
n (%) 1 (3.3%) 0 0.38 Bone, n (%) 0 1 (4.3%) 0.25 Unknown*, n (%) 0 1 (4.3%) 0.25 * Confirmed by elevated tumor marker during follow-up Figure 4 Impact of metastin CA-4948 nmr expression on survival time of pancreatic cancer patients. Overall survival of patients whose tumors were positive (n = 13) or negative (n = AZD1390 in vivo 40) for metastin immunostaining. The survival of patients with tumors positive for GPR54 was significantly longer than that of those with negative tumors (p = 0.02). Prognostic factors according to multivariate analysis Univariate and multivariate analysis were performed to identify parameters associated with overall survival according Tideglusib to the Cox proportional hazards model. The univariate analysis revealed the following five factors to be associated with survival: perineural invasion, pStage, residual tumor, metastin expression, and GPR54 expression. In the multivariate analysis, as well as the UICC pStage (I + II versus IV), overexpression of metastin
was an independent prognostic factor for better survival (hazard ratio, 2.08; 95% confidence interval, 1.05–4.71; p = 0.03) (Table 5). Table 5 Univariate and Multivariate analyses of factors associated with survival after resection in patients with pancreatic cancer. Univariate analysis Multivariate analysis Characteristics Hazard
ratio aminophylline (95% CI) P value Hazard ratio (95% CI) P value Age (continuous variables) 1.01 (0.97–1.1) 0.50 1.03 (0.97–1.1) 0.29 Gender (male versus female) 1.09 (0.73–1.6) 0.66 1.16 (0.73–1.9) 0.52 Location of tumor (head versus body-tail) 1.08 (0.72–1.7) 0.72 0.71 (0.40–1.3) 0.25 Size of tumor (continuous variables) 1.01 (0.97–1.0) 0.63 1.01 (0.96–1.1) 0.69 Histopathological grading (G1 versus G2-4) 1.05 (0.70–1.7) 0.80 0.92 (0.49–1.8) 0.79 pT (pT1, pT2 versus pT3) 1.62 (0.88–4.0) 0.14 2.07 (0.86–6.7) 0.11 pN (pN0 versus pN1) 1.27 (0.85–2.0) 0.25 1.01 (0.58–1.8) 0.97 Lymphatic invasion (positive versus negative) 1.20 (0.80–1.8) 0.33 0.97 (0.54–1.7) 0.92 Venous invasion (positive versus negative) 1.01 (0.68–1.5) 0.95 0.91 (0.52–1.6) 0.73 Perineural invasion (positive versus negative) 1.57 (1.1–2.4) 0.03 1.47 (0.85–2.7) 0.17 pStage (I, II versus IV) 3.16 (1.6–5.8) 0.002 2.70 (1.1–6.8) 0.03 Residual tumor (R0 versus R1) 1.61 (1.0–2.5) 0.03 1.60 (0.91–2.9) 0.10 Metastin expression (positive versus negative) 1.93 (1.1–4.0) 0.01 2.08 (1.1–4.7) 0.03 GPR54 expression (positive versus negative) 1.62 (1.1–2.5) 0.02 1.22 (0.74–2.0) 0.43 Plasma metastin level The mean plasma level of metastin before surgery was 22.7 ± 17.
Related posts:
- Mean values were compared using the student-T test Survival curv
- CD133 mRNA data was expressed as means ± SD, and statistical anal
- DLL4 expression was identified in the cytoplasm and cellular memb
- †Cox proportional hazards regression Boldface type indicates sig
- Additionally, some lymph nodes were disrupted by tumor cells (Fig